ArticleSpine surgery and related research2026
Efficacy of Neurotropin for Chronic Low Back Pain: A Retrospective Observational Study.
Article in Spine surgery and related research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate pain outcomes after Neurotropin initiation in individuals with chronic low back pain (CLBP) and to explore factors associated with treatment response. Methods: This multicenter retrospective observational study included patients with CLBP (duration ≥3 months) who received oral Neurotropin therapy (4 tablets daily) from May 2024 to May 2025. The primary outcome was pain intensity, measured using a visual analog scale (VAS) at baseline and at 2, 4, 8, and 12 weeks. The secondary outcomes were patient characteristics, pain features, simplified Spine painDETECT questionnaire scores, and Brief Scale for Psychiatric Problems in Orthopaedic Patients (BS-POP) scores. Statistical analyses were conducted using paired t-tests with Bonferroni correction, repeated-measures analysis of variance, and multivariate regression. Results: A total of 106 patients (46 males, 60 females; mean age: 66.5±15.8 years) were included. The baseline VAS score was 6.74±1.12. Neurotropin was associated with significant pain reduction over 12 weeks, with VAS scores decreasing to 5.40±1.42 at 2 weeks, 5.15±1.39 at 4 weeks, 4.95±1.38 at 8 weeks, and 4.73±1.48 at 12 weeks (p<0.01 for all). The mean VAS score improvement was 2.14 points (95% confidence interval: 1.76-2.52) at 12 weeks. The minimal clinically important difference (≥1.5 points) was achieved by 62.3% (66/106) of patients. A BS-POP score ≥11 (indicating psychiatric problems) was significantly associated with reduced treatment response (VAS score improvement: 1.45±1.22 vs. 2.38±1.18 points, p=0.001). Pain duration was negatively correlated with treatment response (r=-0.26, p=0.049). No adverse events were reported. Conclusions: Neurotropin was associated with significant pain reduction in CLBP in this retrospective observational study, with an excellent safety profile. Psychiatric comorbidities and longer pain duration were associated with reduced treatment response. Neurotropin may be a beneficial therapeutic option for CLBP, particularly in patients considered unsuitable for long-term non-steroidal anti-inflammatory drug therapy, although these findings require confirmation in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.